Email us for help
Loading...
Premium support
Log Out
Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.
To be added to the distribution list, please email: DDeCastro@southlakeregional.org
In this episode, Dr. Daniel Renouf takes us through the use of Onivyde (NanoLiposomal Irinotecan) in the contemporary management of Pancreatic Ductal Adenocarcinoma. We touch on the use of Nal-Iri in the 2nd line and beyond as well as the first line setting.
Key Opinion Leader: Dr. Daniel Renouf MD. MPH. FRCPC Assistant Professor, UBC Medical Ongologist, BC Cancer.
Host: Shaqil Kassam MD. MSc. FRCPC skassam@southlakeregional.org Medical Oncologist Stronach Regional Cancer Centre, Newmarket, Ontario
Previous episodes: https://www.blogtalkradio.com/medoncnow X @medoncnow